Ultrasonography and cytology previous results analysis in patients that have undergone thyroid surgery

Torrents Laia Capdevila; Marin-Blasco Marta Carrasco; de la Fuente Juarez Mari Cruz; Gomez Maite Santamaria; Vila Alba Dalmau; Cano Carolina Lopez; Riu Ferran Rius

doi:10.1530/endoabs.110.P1189

P1189

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 P1189 | DOI: 10.1530/endoabs.110.P1189

ECEESPE2025 Poster Presentations Thyroid (141 abstracts)

Ultrasonography and cytology previous results analysis in patients that have undergone thyroid surgery

Laia Capdevila Torrents ¹ , Marta Carrasco Marín-Blasco ¹ , Mari Cruz de la Fuente Juárez ² , Maite Santamaría Gómez ² , Alba Dalmau Vila ¹ , Carolina López Cano ¹ & Ferran Rius Riu ¹

Author affiliations

¹Hospital Universitari Arnau de Vilanova de Lleida, Endocrinology and Nutrition, Lleida, Spain; ²Hospital Universitari Arnau de Vilanova de Lleida, General Surgery, Lleida, Spain

JOINT106

Objectives: To review the final pathological results in thyroid nodular disease surgeries and compare them with the previous ultrasonographic and cytological Results.

Patients and Methods: Among the patients that underwent surgery between January 2019 and June 2024, in our database we had at least one ultrasonography and one valid cytology of 304 nodules. EU-TIRADS classification has been used for ultrasound characteristics and the Bethesda system for cytology results.

Results: Among those 304 nodules, 229 (75.3%) had a non-malignant result and 75 (24.7%) malignant. Eleven out of 135 (8.1%) EU-TIRADS 3 were malignant, 22 out of 92 (23.9%) EU-TIRADS 4 and 40 out of 66 (60.6%) EU-TIRADS 5. None of 17 (0%) Bethesda I were malignant, 6 out of 90 (6.7%) Bethesda II, 11 out of 117 (9.4%) Bethesda III, 4 out of 21 (19%) Bethesda IV, 28 out of 34 (82.4%) Bethesda V and 26 out of 26 (100%) Bethesda VI. Combining the two classifications, it can be highlighted that among Bethesda V-VI nodules, 3 out of 7 (42.9%) EU-TIRADS 3 were malignant, 17 out of 19 (89.5%) EU-TIRADS 4, and 32 out of 32 (100%) EU-TIRADS 5. On the other hand, in Bethesda II-III nodules, 7 out of 111 (6.3%) EU-TIRADS 3 were malignant, 3 out of 63 (4.8%) EU-TIRADS 4, and 7 out of 29 (24.1%) EU-TIRADS 5.

Conclusions: The cytology results are highly reliable in our centre (equal or better than the theoretical in Bethesda I and Bethesda III-VI). The apparent high malignancy percentage among Bethesda II nodules can be explained because the reasons why these nodules undergo surgery may give them a higher malignancy risk than those that do not. The interactions between ultrasound and cytology classifications could be used to better assess the indication for surgical treatment.